Literature DB >> 25104571

Pro-inflammatory interferon gamma signaling is directly associated with stroke induced neurodegeneration.

Hilary A Seifert1, Lisa A Collier, Cortney B Chapman, Stanley A Benkovic, Alison E Willing, Keith R Pennypacker.   

Abstract

The delayed immune response to stroke is responsible for the increased neural injury that continues to occur after the initial ischemic event. This delayed immune response has been linked to the spleen, as splenectomy prior to middle cerebral artery occlusion (MCAO) is neuroprotective. Interferon gamma (IFNγ) is linked to the splenic response, which enhances neural injury following MCAO. IFNγ activates the expression of the inflammatory chemokine interferon-inducible protein 10 (IP-10). This study was designed to determine the role of IFNγ signaling in the inflammatory response following MCAO. Expression of IP-10 increased in the brain and the spleen following MCAO. Splenectomy inhibited the increase of IP-10 in the brain post-MCAO, while recombinant IFNγ administration to splenectomized rats returned IP-10 levels in the brain to levels found in rats after MCAO only. Systemic administration of an IFNγ neutralizing antibody to MCAO-treated rats reduced infarct volume and IP-10 levels in the brain. T cell infiltration was reduced in the MCAO-damaged brains of IFNγ antibody-treated animals relative to those that received isotype control antibodies. Additionally, inhibiting IFNγ signaling with splenectomy or an IFNγ neutralizing antibody blocked the induction of IP-10 expression and decreased neurodegeneration following MCAO. Targeting this pro-inflammatory pathway following stroke could be a promising stroke therapeutic.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25104571      PMCID: PMC4209188          DOI: 10.1007/s11481-014-9560-2

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  28 in total

1.  Human umbilical cord blood cells directly suppress ischemic oligodendrocyte cell death.

Authors:  A A Hall; A G Guyer; C C Leonardo; C T Ajmo; L A Collier; A E Willing; K R Pennypacker
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

2.  The splenic response to ischemic stroke: what have we learned from rodent models?

Authors:  Christopher C Leonardo; Keith R Pennypacker
Journal:  Transl Stroke Res       Date:  2011-04-03       Impact factor: 6.829

3.  Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke.

Authors:  Arthur Liesz; Wei Zhou; Éva Mracskó; Simone Karcher; Henrike Bauer; Sönke Schwarting; Li Sun; Dunja Bruder; Sabine Stegemann; Adelheid Cerwenka; Clemens Sommer; Alexander H Dalpke; Roland Veltkamp
Journal:  Brain       Date:  2011-03       Impact factor: 13.501

Review 4.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

5.  Splenectomy-reduced hepatic injury induced by ischemia/reperfusion in the rat.

Authors:  Y Okuaki; H Miyazaki; M Zeniya; T Ishikawa; Y Ohkawa; S Tsuno; M Sakaguchi; M Hara; H Takahashi; G Toda
Journal:  Liver       Date:  1996-06

6.  A transient decrease in spleen size following stroke corresponds to splenocyte release into systemic circulation.

Authors:  Hilary A Seifert; Aaron A Hall; Cortney B Chapman; Lisa A Collier; Alison E Willing; Keith R Pennypacker
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-06       Impact factor: 4.147

7.  Acute splenic irradiation reduces brain injury in the rat focal ischemic stroke model.

Authors:  Robert P Ostrowski; Reinhard W Schulte; Ying Nie; Ted Ling; Timothy Lee; Anatol Manaenko; Daila S Gridley; John H Zhang
Journal:  Transl Stroke Res       Date:  2012-12       Impact factor: 6.829

8.  The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3.

Authors:  P Loetscher; A Pellegrino; J H Gong; I Mattioli; M Loetscher; G Bardi; M Baggiolini; I Clark-Lewis
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

9.  The spleen contributes to stroke-induced neurodegeneration.

Authors:  Craig T Ajmo; Dionne O L Vernon; Lisa Collier; Aaron A Hall; Svitlana Garbuzova-Davis; Alison Willing; Keith R Pennypacker
Journal:  J Neurosci Res       Date:  2008-08-01       Impact factor: 4.164

10.  Reversible middle cerebral artery occlusion without craniectomy in rats.

Authors:  E Z Longa; P R Weinstein; S Carlson; R Cummins
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

View more
  44 in total

1.  Acute splenic responses in patients with ischemic stroke and intracerebral hemorrhage.

Authors:  Farhaan S Vahidy; Kaushik N Parsha; Mohammad H Rahbar; MinJae Lee; Thanh-Tung Bui; Claude Nguyen; Andrew D Barreto; Arvind B Bambhroliya; Preeti Sahota; Bing Yang; Jaroslaw Aronowski; Sean I Savitz
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-02       Impact factor: 6.200

2.  Chrysophanol affords neuroprotection against microglial activation and free radical-mediated oxidative damage in BV2 murine microglia.

Authors:  Fuqing Lin; Chen Zhang; Xianzhen Chen; E Song; Shiyu Sun; Minghui Chen; Tao Pan; Xiaoming Deng
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Targeting the peripheral inflammatory response to stroke: role of the spleen.

Authors:  Keith R Pennypacker
Journal:  Transl Stroke Res       Date:  2014-09-26       Impact factor: 6.829

Review 4.  Clinical Trials of Immunomodulation in Ischemic Stroke.

Authors:  Roland Veltkamp; Dipender Gill
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 5.  Immune responses in stroke: how the immune system contributes to damage and healing after stroke and how this knowledge could be translated to better cures?

Authors:  Aditya Rayasam; Martin Hsu; Julie A Kijak; Lee Kissel; Gianna Hernandez; Matyas Sandor; Zsuzsanna Fabry
Journal:  Immunology       Date:  2018-03-26       Impact factor: 7.397

6.  Functional improvement and immune-inflammatory cytokines profile of ischaemic stroke patients after treatment with boswellic acids: a randomized, double-blind, placebo-controlled, pilot trial.

Authors:  Somayeh Mahmoodi Baram; Saeed Karima; Somayeh Shateri; Abbas Tafakhori; Akbar Fotouhi; Behnam Safarpour Lima; Shima Rajaei; Meisam Mahdavi; Hessam Sepasi Tehrani; Vajiheh Aghamollaii; Seyed Hossein Aghamiri; Behnam Mansouri; Sina Gharahje; Samaneh Kabiri; Maryamosadat Hosseinizadeh; Shima Zare Shahamati; Amir Taher Alborzi
Journal:  Inflammopharmacology       Date:  2019-08-12       Impact factor: 4.473

Review 7.  Immune interventions in stroke.

Authors:  Ying Fu; Qiang Liu; Josef Anrather; Fu-Dong Shi
Journal:  Nat Rev Neurol       Date:  2015-08-25       Impact factor: 42.937

8.  Distinct peripheral blood monocyte and neutrophil transcriptional programs following intracerebral hemorrhage and different etiologies of ischemic stroke.

Authors:  Paulina Carmona-Mora; Bradley P Ander; Glen C Jickling; Cheryl Dykstra-Aiello; Xinhua Zhan; Eva Ferino; Farah Hamade; Hajar Amini; Heather Hull; Frank R Sharp; Boryana Stamova
Journal:  J Cereb Blood Flow Metab       Date:  2020-09-22       Impact factor: 6.200

9.  Lipopolysaccharide worsens the prognosis of experimental cerebral ischemia via interferon gamma-induced protein 10 recruit in the acute stage.

Authors:  Ping Wang; Jiaqi Zhang; Feifei Guo; Shuang Wang; Yi Zhang; Defeng Li; Haiyu Xu; Hongjun Yang
Journal:  BMC Neurosci       Date:  2019-12-27       Impact factor: 3.288

10.  Depletion of CD4 T cells provides therapeutic benefits in aged mice after ischemic stroke.

Authors:  Nia M Harris; Meaghan Roy-O'Reilly; Rodney M Ritzel; Aleah Holmes; Lauren H Sansing; Lena M O'Keefe; Louise D McCullough; Anjali Chauhan
Journal:  Exp Neurol       Date:  2020-01-15       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.